Sir2 (silent information regulator-2), an NAD -dependent histone deacetylase, is highly conserved in organisms ranging from archaea to humans. Yeast Sir2 is responsible for silencing at repeated DNA sequences in mating-type loci, telomeres and rDNA, and plays critical roles in DNA repair, stress resistance and longevity. The phenomenon of human aging is known to be a critical cardiovascular risk factor. Senescence of endothelial cells has been proposed to be involved in vascular dysfunction and atherogenesis. Recent studies have demonstrated that mammalian Sirt1 NAD -dependent protein deacetylase, the closest homologue of Sir2, regulates vascular angiogenesis, homeostasis and senescence. This review focuses on SIRT1 as a potential therapeutic target against atherosclerosis. , 2010; 17:431-435. diverse species. Sir2 has been identified as an NADdependent histone deacetylase and is responsible for maintenance of chromatin silencing and genome stability 3) . Sir2 genes are conserved during evolution, and seven homologs of sirtuins (Sirt1-7 ) have been cloned in mammals. Mammalian sirtuins have diverse cellular localizations, modify multiple substrates, and affect cellular functions. SIRT1 is localized in the cytoplasm and nucleus, and SIRT6 and SIRT7 are localized in the nucleus. SIRT3, SIRT4 and SIRT5 reside in the mitochondria and SIRT2 is localized in the cytoplasm. SIRT1, SIRT2, SIRT3 and SIRT5 are NAD -dependent deacetylases, whereas SIRT4 and SIRT6 are primarily mono-ADP-ribosyl transferases. SIRT1, the closest homologue of Sir2, targets a wide range of transcriptional regulators, including p53, PML (promyelocytic leukemia protein), FoxO (forkhead box O), NF-B (nuclear factor B) and PPAR-(peroxisome proliferators-activated receptor-) [4] [5] [6] [7] [8] . Like yeast Sir2, SIRT1 regulates the cell cycle, senescence, apoptosis and metabolism, and might act as a longevity factor in mammals.
Introduction
Recent studies demonstrate that cellular senescence is involved in various pathological conditions, such as atherosclerosis. In this review, we discuss the potential protective effect of SIRT1 on vascular endothelial cells.
Sirtuins
During the last decade, aging research has progressed through the use of lower organism models, such as the budding yeast Saccharomyces cerevisiae and the nematode Caenorhabditis elegans. In S. cerevisiae, the Sir2 (silent information regulator-2) family of genes governs budding exhaustion and replicative life span 1, 2) ; deletions of Sir2 shorten life span and an extra copy of this gene increases life span. In addition to promoting longevity, the activity of Sir2 is enhanced by caloric restriction (CR), which extends life span in be a critical cardiovascular risk factor. Minamino et al. proposed that the senescence of endothelial cells is involved in endothelial dysfunction and atherogenesis 9) . Histological study of human atherosclerotic lesions has demonstrated the existence of vascular cells that exhibit the morphological features of senescence 10) .
Moreover, it has been reported that angiogenesis becomes impaired with advancing age 11) and that aging reduces the antithrombogenic properties of the endothelium 12) . These senescent changes of vascular structure and function have been suggested to result in the increased risk of atherosclerotic cardiovascular disease in the elderly.
According to the free-radical theory, reactive oxygen species (ROS) may be potential candidates responsible for vascular dysfunction and atherosclerosis 13) , and upon the production of high levels of ROS, the redox balance is disturbed and cells shift into a state of oxidative stress, which subsequently leads to endothelial dysfunction and senescence with shortening of telomeres 14) . Endothelial NO synthase (eNOS) activity is reduced in human senescent endothelial cells, accompanied by a reduction of nitric oxide (NO) production. Endothelial-derived NO regulates vascular relaxation and has athero-protective effects 15) . Intriguingly, endothelial NO can protect against a state of oxidative stress, and activation of eNOS and subsequent production of NO delay endothelial cellular senescence 16, 17) .
SIRT1 Plays a Critical Role in Endothelial Homeostasis
SIRT1 likely plays a critical role in endothelial homeostasis by regulating endothelial nitric oxide synthase (eNOS). A recent study showed that levels of cGMP and eNOS are elevated in tissues of calorierestricted mice, and production of NO by CR increases SIRT1 expression. The induction of SIRT1 expression is blunted in eNOS-deficient mice, and eNOS has been implicated in regulation of the expression of SIRT1 18) .
It has been reported that SIRT1 promotes endothelial-dependent vasodilation by targeting eNOS for deacetylation, leading to enhanced NO production 19) . Intriguingly, SIRT1 has been shown to directly bind to eNOS, which is deacetylated at lysines 496 and 506 in the calmodulin-binding domain and posttranscriptionally leads to activation of eNOS. Inhibition of SIRT1 by a deacetylase-defective mutant SIRT1 decreases NO bioavailability and inhibits endothelium-dependent vasorelaxation. Consistent with these results, we showed that SIRT1 inhibition by sirtinol or RNAi-mediated knock down induced a premature senescent phenotype in human endothelial cells. Conversely, overexpression of SIRT1 prevented oxidative stress-induced endothelial senescence 20) . Intriguingly, a micro RNA (miR-217) was recently identified and miR-217 induced endothelial senescence through direct inhibition of SIRT1 21) .
In addition to endothelial protection, SIRT1 regulates the angiogenic activity of endothelial cells. It has been reported by Potente et al. that SIRT1 deacetylase activity plays a critical role in the angiogenesis of endothelial cells 22) . Knockdown of SIRT1, but not SIRT2-7, was uniquely associated with loss of sprouting angiogenesis in vitro. Moreover, Sirt1 mutant mice, which have genetic deletion of SIRT1 activity in the endothelium postnatally, have impaired formation of new vessels in response to angiogenic signals such as ischemic stress.
Cilostazol Inhibits Oxidative Stress-Induced Premature Senescence via Up-Regulation of SIRT1 in Human Endothelial Cells
A PDE3 inhibitor, cilostazol, is used as a vasodilating anti-platelet drug for treating intermittent claudication, and in preclinical studies was shown to have a protective effect on endothelial cells by increasing eNOS activity 23) . Cilostazol increases intracellular cAMP content accordingly and activates protein kinase A (PKA) and PI3K/Akt signaling 24) . We found that treatment with cilostazol inhibited the senescent phenotype. Cilostazol increased eNOS activity, expression of eNOS and the phosphorylation of eNOS at Ser 1177 in parallel with the phosphrylation of Akt at Ser 473 . These results suggest that the protective effect against a senescent phenotype may be attributable to an increase in NO via eNOS activation by cilostazol 25) .
To explore the mechanism by which cilostazol prevents endothelial senescence, we considered that an increase in NO production could promote the longevity gene, SIRT1. We found that cilostazol significantly increased SIRT1 mRNA and protein in a concentration-dependent manner. In contrast, SIRT1 inhibition abrogated the effect of cilostazol on specific senescent changes. Although NO is known to be involved in reducing oxidative stress and the progression of atherosclerosis, we suggest that the NO-mediated prevention of senescence is attributable to SIRT1 function (Fig. 1) . These findings implicate the eNOS-NO-SIRT1 axis as one of the fundamental determinants of endothelial senescence, and the role of SIRT1 as a driver of cellular stress resistance and longevity is note-worthy in the context of its expression profile (Fig. 2) .
In addition to these results, we found that drugs utilized for drug-eluting stents (DES), including paclitaxel and limus family members (e.g. sirolimus, everolimus), inhibit the growth of endothelial cells and lead to endothelial senescence caused by delayed re-endothelialization 26) . We showed that the development of endothelial senescence induced by sirolimus and everolimus is SIRT1-dependent, whereas paclitaxel acts through a SIRT1-independent pathway. Because the effects of sirolimus and everolimus involve SIRT1 modulation, cilostazol reverses sirolimus-or everolimus-induced senescence. Our results could have the interesting clinical implication that triple anti-platelet therapy may have more beneficial effects on endothelial senescence than standard dual therapy with sirolimus-or everolimus-eluting stents.
Activation of SIRT1, a Potential Therapeutic Target against Atherosclerosis
CR extends life span in diverse species. A recent study by Colman et al. at Wisconsin National Primate Center (WNPRC) reported that calorie-restricted Rhesus macaques showed a lower incidence of agerelated diseases, such as cancer, diabetes, and cardiovascular disease, and lower age-related mortality 27) . Resveratrol, a CR mimetic, is a polyphenolic activator of SIRT1. Resveratrol increases mitochondrial biogenesis in endothelial cells via the activation of eNOS and SIRT1 28) . Resveratrol has also been shown to increase the expression of eNOS, and a combination of resveratrol with an HMG-CoA reductase inhibitor (statin) increased the activation of eNOS, resulting in increased functional recovery in a model of acute myocardial infarction 29) . Therefore, we suggest that increased NO bioavailability by other pharmaceutical products, such as statins, or agents with phytoestrogenic properties, such as resveratrol, may exert a protective effect against endothelial senescence via up-regulation of eNOS and SIRT1, and this possibility deserves further investigation. Our results and the findings by other laboratories indicate that micromolar levels of resveratrol are sufficient to exert vasculoprotective effects 26, 30) . Considering that each gram of fresh grape skin contains 50 − 100 g resveratrol and it is found mainly in high-quality red wine at a concentration of 20 to 60 mol/L as previously reported 31) , it becomes apparent that effective concentrations are unlikely to be reached in plasma in vivo. However, resveratrol is a lipophilic substance, and exhibits higher bioavailability and slower clearance, and has been shown to accumulate in tissues such as the heart, liver, and kidney 32) . By daily consumption of grapes, berries, red wine or dietary supplements containing resveratrol, an effective concentration of resveratrol may be achievable in vivo. Recently, novel small molecule activators of Sirt1 (SRTs), even 1000-fold more potent than resveratol, have been identified (Sirtris Pharmaceuticals Inc., Boston, USA) 33) . SRTs induce many of the beneficial metabolic changes observed with CR/resveratrol treat- ment 34) . We propose that using these chemical agents to activate SIRT1 may be a new attractive therapy for protection against vascular senescence, dysfunction and atherosclerosis.
Conclusions
SIRT1 is likely to play an important role in the prevention of human cardiovascular disease, including atherosclerosis. There is some evidence that SIRT1 interacts with the vascular eNOS/NO system. Just as the French paradox stands out as an excellent example of a reduced incidence of cardiovascular disease, activation of SIRT1 may have a beneficial effect on vascular senescence, dysfunction and atherosclerosis.
